News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points Interested in Nuvation Bio Inc.? Here are five stocks we like better. IBTROZI momentum strengthened: Second-quarter revenue reached $31.7 million, including $23.2 million in U.S. product revenue, up 25% sequentially. About 85% of new patient starts were first-line, supporting longer treatment durations …
Nuvation Bio (NYSE: NUVB) announced Q2 2026 revenue of $31.7 million, driven by strong sales of its ROS1 inhibitor IBTROZI and collaboration agreements, representing a significant increase from the previous year. Despite the revenue growth, the company reported a net loss of $62.8 million …
Nuvation Bio (NUVB) presented a corporate summary highlighting its focus on oncology medicines and strong financial position. The company emphasized the success of IBTROZI (taletrectinib), approved for advanced ROS1+ NSCLC, noting its high efficacy, favorable safety profile, and significant market potential. The presentation also …
Search by ticker symbol or company name and select a result to open its chart.